Kerri L. Bouchard, ACNP-BC

Kerri Bouchard practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Kerri Bouchard's NPI, 1144588294, was assigned on April 26, 2012. Kerri Bouchard holds Maryland license R130529.

Kerri Bouchard's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Kerri Bouchard's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Kerri Bouchard is also affiliated with University of Maryland Medical Center Midtown Campus. The medical group on file is University of Maryland Neurology Associates, P.A. Dmand AI also links Kerri Bouchard to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kerri Bouchard practices, 5 sites in all. Vendor and product names are available with a free account.

Acute care is Kerri Bouchard's primary specialty in the NPI Registry, under taxonomy code 363LA2100X. Kerri Bouchard is licensed in Maryland.

CMS counts 48 Medicare patients who saw Kerri Bouchard in 2024. The largest group is 65 to 74, with 23 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kerri Bouchard's median patient age at 65, with 61% women.

In 2024, Kerri Bouchard wrote 198 Medicare Part D claims for 50 patients. 80% of them were for generic drugs.

Kerri Bouchard accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Kerri Bouchard as offering telehealth.

CMS Open Payments shows 1 general payment to Kerri Bouchard from 1 drug or device company in 2025. Education make up the largest share, 100% of the total. Mitsubishi Tanabe Pharma America, Inc. paid the most, $15.